Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2024 | PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions

Joshua Sabari, MD, NYU Langone Health, New York, NY, provides an overview of the Phase III PAPILLON (NCT04538664) trial of amivantamab plus chemotherapy (ami-chemo) versus chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC).The trial showed a significant improvement in progression-free survival (PFS) with amivantamab plus chemotherapy, nearly doubling the median PFS compared to chemotherapy alone. The regimen has been approved by the FDA as a frontline treatment for patients with EGFR exon 20 mutant NCSLC, establishing a new standard of care. This interview took place at the ELCC 2024 meeting in Prague, Czech Republic.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.